# Interaction of nitrogen dioxide with human plasma

## Antioxidant depletion and oxidative damage

## Barry Halliwell<sup>a</sup>, Miao-Lin Hu<sup>a</sup>, Samuel Louie<sup>a</sup>, Timothy R. Duvall<sup>b</sup>, Brian K. Tarkington<sup>b</sup>, Paul Motchnik<sup>c</sup> and Carroll E. Cross<sup>a</sup>

\*Pulmonary-Critical Care Medicine, U.C. Davis Medical Center, 4301 X Street, Sacramento, CA 95817, USA, <sup>b</sup>California Primate Research Center, UC Davis, Davis, CA 95616, USA and <sup>c</sup>Division of Biochemistry and Molecular Biology, Barker Hall, UC Berkeley, CA 94720, USA

#### Received 4 September 1992

Nitrogen dioxide (NO<sub>3</sub>) is often present in inhaled air and may be generated in vivo from nitric oxide. Exposure of human blood plasma to NO<sub>2</sub><sup>\*</sup> caused rapid losses of ascorbic acid, uric acid and protein thiol groups, as well as lipid peroxidation and depletions of  $\alpha$ -tocopherol, bilirubin and ubiquinol-10. No increase in protein carbonyls was detected. Supplementation of plasma with ascorbate decreased the rates of lipid peroxidation,  $\alpha$ -tocopherol depletion and loss of uric acid. Uric acid supplementation decreased rates of lipid peroxidation but not the loss of  $\alpha$ -tocopherol. We conclude that ascorbic acid, protein -SH groups, uric acid and  $\alpha$ -tocopherol may be important agents protecting against NO<sub>2</sub><sup>\*</sup> in vivo. If these antioxidants are depleted, peroxidation of lipids occurs and might contribute to the toxicity of NO<sub>2</sub><sup>\*</sup>.

Nitrogen dioxide; Lipid peroxidation; Ascorbic acid; Nitric oxide; Uric acid; Antioxidant

## 1. INTRODUCTION

Nitrogen dioxide  $(NO_2^*)$  is a powerfully-oxidizing reactive brown gas with established pulmonary toxicity [1-6]. It can be present in homes with unvented heating sources at concentrations up to 2 ppm, in mainstream cigarette smoke (>50 ppm), in smog (up to 1 ppm) and in smoke from other burning organic materials [6-8].  $NO_2^*$  might also be formed in vivo by reaction of  $O_2$  with nitric oxide (NO\*), which is generated (as the 'endothelium-derived relaxing factor') by vascular endothelial cells, and also by other cell types (reviewed in [9]). Nitric oxide might also react with superoxide ( $O_2^{*-}$ ) radical in vivo to give peroxynitrite, which decomposes to yield  $NO_2^*$  [10]. There is considerable current interest in the toxicity and mutagenicity of nitrogen oxides [1-8,11,12].

 $NO_2^{\circ}$  possesses an unpaired electron and is thus a free radical [13]. For example,  $NO_2^{\circ}$  can stimulate lipid peroxidation, and end-products of peroxidation are present in the lung lining fluids of rats after  $NO_2^{\circ}$  exposure [14– 16].  $NO_2^{\circ}$  can also damage proteins [6] and it is not yet clear which targets of attack by  $NO_2^{\circ}$  are the most important in vivo. Also, human body fluids and tissues contain a wide range of antioxidant defence systems (reviewed in [17,18]), and it seems likely that they might offer some protection against damage by  $NO_2^{\circ}$ . Thus any NO<sub>2</sub><sup>•</sup> formed from NO<sup>•</sup> (by reaction with O<sub>2</sub>) in vivo will presumably react with antioxidants in human extracellular fluids. Inhaled NO<sub>2</sub><sup>•</sup> probably undergoes considerable interaction with antioxidants and other constituents of lung lining fluids [19]. However, the *relative* importance of different antioxidant defences in protecting against NO<sub>2</sub><sup>•</sup> has not yet been established, although several authors have suggested that  $\alpha$ -tocopherol may be important [20,21].

In the present paper, we have investigated the reaction of  $NO_2^*$  with antioxidants in freshly-prepared human plasma as a model for both situations [22], especially as methods for measuring antioxidants and oxidative damage in plasma are well-established [17,18,22,23]. We attempted to measure  $NO_2^*$ -induced oxidative damage in several ways: loss of protein -SH groups, inactivation of enzymes, formation of protein carbonyls [24] and formation of lipid hydroperoxides, as measured by a specific HPLC-based chemiluminescence method [23,25].

## 2. EXPERIMENTAL

#### 2.1. Materials

All reagents were of the highest quality available from Sigma. Blood from healthy adult male volunteers was collected into heparinized tubes and centrifuged at  $1,000 \times g$  and  $4^{\circ}C$  for 10 min to obtain plasma, which was used immediately.

#### 2.2. Exposure to NO:

Plasma was diluted 80:20 with 0.5 M KH<sub>2</sub>PO<sub>4</sub>/K<sub>2</sub>HPO<sub>4</sub> buffer, pH

Correspondence and present address: B Halliwell, Pharmacology Group, Kings College, Chelsea Campus, Manresa Road, London SW3 6LX, UK.

7.4, to maintain pH during exposures to NO<sub>2</sub>. A correction has been made for this dilution factor in the results presented. 3 ml aliquots were placed into 6 ml Faicon plates (3 cm diameter) in a controlledenvironment exposure chamber (Primate Center, UC Davis) in which a steady concentration of 14 ppm of NO2 was maintained. NO2 was generated by bubbling nitrogen through the liquid dimer, N<sub>2</sub>O<sub>4</sub>, held at  $0^{\circ}$ C [26]. The NO<sub>2</sub> (in N<sub>2</sub>) was conveyed to the mixing inlet of the chamber through stainless-steel lines. Flow was automatically controlled with a mass flow controller (Tylan General, Torrance, CA; Model FC-2900KZ). Chamber NO<sub>2</sub> concentration was monitored with a chemiluminescent oxide of nitrogen analyzer (Dasibi Corp., Glendale, CA; Model 2108). The monitor was calibrated by gas-phase titration of ozone with nitric oxide [27] and periodically checked against nitric oxide span gas of known concentration. Humidity was 40-60% and temperature 25-27°C. Plasma aliquots were also incubated for the same time periods in an identical chamber containing filtered air. At the end of the exposure, the plates were removed, the volume of plasma diluted back to 3 ml (if necessary) with distilled water and aliquots taken for the various assays.

#### 2.3. Assays of antioxidants

Ascorbic acid, uric acid and lipid hydroperoxides were measured by HPLC [25], as was  $\alpha$ -tocopherol [28]. Plasma sulfhydryl (-SH) groups were determined using Ellman's reagent, 5.5'-dithiobis(2-nitrobenzoate), DTNB. Fifty  $\mu$ l of plasma was mixed with 1.0 ml of 0.1 M Tris buffer, containing 10 mM EDTA, pH 8.2. Any absorbance at 412 nm contributed by the plasma alone was subtracted from that obtained from the same sample 20 min after addition of 40  $\mu$ l of 10 mM DTNB. A blank containing DTNB only was also included, and -SH concentration was calculated using a molar extinction coefficient of 13,600 M<sup>-1</sup>·cm<sup>-1</sup> at 412 nm. Protein carbonyls were measured spectrophotometrically by a modification [29] of the method in [24]. Total bilirubin was measured by using a Beckman Synchron CX4 autoanalyzer, as were the activities of lactate dehydrogenase, aspartate aminotransferase,  $\gamma$ -glutamyltransferase and creatine kinase.

In some experiments, the effect of NO<sup>2</sup><sub>2</sub> exposure upon the electrophoretic migration of plasma lipoproteins was examined by agarose gel electrophoresis of NO<sup>2</sup><sub>2</sub>-exposed or air-exposed plasma, using Beckman Paragon Lipid gels run according to the manufacturer's recommendations. Gels were stained with fat 7B stain.

#### 3. RESULTS

Freshly-prepared human plasma was exposed to 14 ppm NO<sub>2</sub><sup>5</sup> for various times. The value of 14 ppm may seem high in relation to the concentrations of NO<sub>2</sub><sup>5</sup> reported in polluted air (usually <1 ppm), but it was used because the surface:volume ratio in our Falcon plates is far lower than the enormous ratio found in the respiratory tract. In addition, such high NO<sub>2</sub><sup>5</sup> concentrations are found in mainstream cigarette smoke and smoke from other burning organic materials [6–8] and might also be achieved in the vicinity of activated phagocytes [11,12]. We buffered the plasma against pH changes by adding a small amount of concentrated phosphate buffer.

Exposure of human plasma to NO<sup>2</sup> produced a rapid loss of ascorbic acid, uric acid and protein -SH groups. In percentage terms, ascorbic acid was always lost at the greatest rate, with uric acid being lost slightly more slowly (reproducible in 8 different experiments utilizing plasma from 5 different donors). Fig. 1 shows a representative experiment. However, one must also consider the fact that the concentration of ascorbic acid in plasma is much lower than that of uric acid or protein -SH [17]. For example, after 1 h exposure to 14 ppm NO<sub>2</sub>, the following losses of antioxidants were observed (mean  $\pm$  SD for 5 different plasma samples): ascorbate 49.9  $\pm$  15.8  $\mu$ M, uric acid 118  $\pm$  41  $\mu$ M and protein -SH groups 76  $\pm$  48  $\mu$ M. These results are corrected for the slow losses observed in the air-exposed controls (Fig. 1). Hence all three antioxidants appear to make a significant contribution to scavenging NO<sub>2</sub>, but uric acid seems to be quantitatively the most important.

Exposure of plasma to NO<sup>5</sup> for 1 h led to the formation of lipid hydroperoxides and loss of  $\alpha$ -tocopherol (Fig. 1D). Lipid peroxidation and loss of  $\alpha$ -tocopherol accelerated after 3 h exposure, when ascorbate and uric acid had been almost completely lost. Cholesterol ester hydroperoxides were the major species formed (mean  $\pm$ SD, 2.9  $\pm$  1.8  $\mu$ M for 3 different plasma samples after 6 h exposure to NO<sub>2</sub>), whereas levels of phospholipid hydroperoxides in the same experiments were only 0.03–0.18  $\mu$ M. There was also loss of ubiquinol, another lipid-soluble antioxidant [30,31], in NO<sub>2</sub>-exposed plasma. For example, whereas 6 h of exposure to NO5 depleted  $\alpha$ -tocopherol in human plasma from 40.6  $\pm$  5.7  $\mu$ M (mean ± SD, 5 different plasma samples) to 20.5 ± 4.0  $\mu$ M, ubiquinol was completely lost (0.95 ± 0.05  $\mu$ M to zero; n = 3).

The starting concentrations of ascorbic acid in plasma samples from different donors varied from 34  $\mu$ M to 227  $\mu$ M (the latter in a subject consuming vitamin C supplements). Inspection of the data suggested that the initial rate of uric acid depletion, but not that of protein ~SH, was slower in plasmas containing the higher ascorbate concentrations. The effect of adding additional ascorbate to plasma upon the rates of oxidative damage and antioxidant depletion was therefore examined. Fig. 1 shows a representative experiment using 1 mM added ascorbate. Added ascorbate (1 mM) was oxidized fast by NO<sub>2</sub>, but some remained even after 5 h exposure (Fig. 1A). This ascorbate supplementation greatly slowed the NO<sub>2</sub>-induced loss of uric acid (Fig. 1C); it also reproducibly slowed the accumulation of lipid hydroperoxides and the loss of  $\alpha$ -tocopherol (Fig. **ID**). By contrast, ascorbate addition had no significant effect upon the loss of protein -SH groups (Fig. 1B). Lower ascorbate concentrations (0.2-0.5 mM) were also protective, but to a lesser extent (data not shown). The effects of supplementing plasma with uric acid and GSH were also examined. GSH, an antioxidant known to be present in lining fluids of the lower respiratory tract [32,33], did not inhibit lipid peroxidation or  $\alpha$ tocopherol depletion, even when added at 1 mM final concentrations. By contrast, adding an additional 0.5 mM uric acid to plasma decreased the concentration of total lipid hydroperoxides after exposure to NO<sub>2</sub> for 6 h by a mean of 55% in two experiments. However,



Fig. 1. Effects of exposing plasma to NO<sub>2</sub><sup>\*</sup>. A representative experiment is shown in which all measurements were made on the same plasma samples. Each data point is the mean of at least duplicate determinations that differed by <10%. (A) Loss of ascorbic acid. (•) NO<sub>2</sub><sup>\*</sup>; (m) NO<sub>2</sub><sup>\*</sup>, plasma supplemented with an additional 1 mM ascorbic acid; (•) air exposed control; (□) air control + ascorbate. (B) Sulfhydryl groups. (•) NO<sub>2</sub><sup>\*</sup>; (m) NO<sub></sub>

uric acid did not significantly affect the loss of  $\alpha$ -tocopherol.

The carbonyl assay, which measures oxidative damage to several amino acid residues in proteins [24], was used to look for  $NO_2^*$ -induced protein damage involving amino acid residues other than -SH. Reaction of  $NO_2^*$ with plasma led to the formation of a pale yellow-orange chromogen. When allowance was made for this, no increase in protein carbonyls was detected even after exposure of plasma to  $NO_2^*$  for 6 h. Similarly, this 6 h  $NO_2^*$  exposure produced no changes in the electrophoretic mobility of plasma low-density lipoproteins (LDL) when compared with air-exposed controls, nor did it change the activities of the enzymes lactate dehydrogenase, aspartate aminotransferase and gammaglutamyl transferase in plasma. Creatine kinase activity was slightly but reproducibly decreased (by  $16 \pm 5\%$ , n=3) by 6 h of exposure to  $NO_2^*$ . This exposure also decreased total plasma bilirubin from  $0.8 \pm 0.4$  mg/dl (n=3) to  $0.3 \pm 0.2$  mg/dl.

## 4. DISCUSSION

In the present paper, we have studied the reaction of NO<sup>2</sup> with human plasma to gain information about the possible fates of NO<sub>2</sub> generated in vivo (e.g. from endogenous NO<sup>•</sup> [10]) and of NO<sup>•</sup><sub>2</sub> present in polluted inhaled air. Ascorbic acid, protein -SH groups and especially uric acid all appear to be important scavengers of NO<sub>2</sub>, being rapidly depleted when plasma is exposed to this gas. Addition of extra ascorbate to plasma slowed loss of uric acid. Indeed, 1 mM ascorbate appeared to reproducibly increase plasma uric acid concentrations in the early stages of NO<sub>2</sub> exposure (by 11  $\pm$  14%, *n*=5, after 30 min), for an unknown reason. This prevention of uric acid loss may occur because ascorbic acid is oxidized faster than uric acid (Fig. 1) and so 'spares' uric acid. An additional reason may be that reaction of NO<sub>2</sub> (a free radical) with uric acid produces a uric acid radical that can be re-converted to uric acid by ascorbate: such a 'recycling' of uric acid radicals has been demonstrated in vitro [34,35].

It is frequently suggested that NO<sup>2</sup> toxicity involves lipid peroxidation [1,5,6,14,15,21,36]. Our data are consistent with this view, in that exposure of plasma to 14 ppm NO; led to peroxidation of lipids and depletion of the lipid-soluble antioxidants ubiquinol-10 and  $\alpha$ -tocopherol. Supplementing plasma with ascorbic acid slowed the loss of  $\alpha$ -tocopherol. Ascorbate could act by preferentially scavenging NO<sub>2</sub>, so protecting the lipid. Ascorbate also recycles  $\alpha$ -tocopherol radicals back to  $\alpha$ -tocopherol. Adding additional uric acid also slowed lipid peroxidation, perhaps by preferentially scavenging NO<sub>2</sub>, but it did not preserve  $\alpha$ -tocopherol. By contrast, apart from the rapid loss of protein -SH groups, little evidence for NO<sup>2</sup> induced oxidative damage to proteins was provided by measurements of enzyme inactivation or protein carbonyl formation.

Although we observed NO<sub>2</sub>-induced lipid peroxidation in plasma under our experimental conditions, there were no changes in the electrophoretic mobility of LDL, despite the fact that peroxidation of LDL frequently causes such changes [37]. This could mean that insufficient peroxides were formed in the LDL, or that the peroxides were not decomposed into aldehydes that could modify apoprotein B and change the electrophoretic mobility of the LDL [37]. Further work is needed to investigate these possibilities.

It is interesting to compare the effects of NO<sup>5</sup><sub>2</sub> on plasma with those exerted by another common air-pollutant, the non-radical ozone (O<sub>3</sub>). Uric acid, ascorbic acid and protein -SH are again important scavengers of O<sub>3</sub> in plasma [22]. Uric acid has been suggested to play a particularly-important scavenging role against O<sub>3</sub> in the human upper respiratory tract [22,38]: our data suggest that it may also be protective against NO<sub>2</sub>. However, exposure to O<sub>3</sub> produced little lipid peroxidation in plasma in our previous experiments, whereas significant protein damage was detected by the carbonyl assay [22,39]. Hence, inhaled O<sub>3</sub> and NO<sub>2</sub> may attack different molecular targets in vivo. Perhaps this is relevant to suggestions that inhalation of mixtures of these gases produces synergistic biological damage [40].

Acknowledgements: The authors are grateful to NIH (Grants HL47628, RR-00169 and ES-00628) for research support. We also thank Paul Davis, Ph.D. for help with the Lipogel analysis.

## REFERENCES

- Mustafa, M.G. and Tierney, D.F. (1978) Am. Rev. Resp. Dis. 118, 1061–1090.
- [2] Crapo, J.D., Marsh-Salin, J., Ingram, P. and Pratt, P.D. (1978)
  J. Appl. Physiol. 44, 370-379.
- [3] Evans, M.J. (1984) Environ. Health. Perspect. 55, 85-95.
- [4] Frampton, M.W., Morrow, P.E., Cox, C., Gibb, F.R., Speers, D.M. and Utell, M.J. (1991) Am. Rev. Resp. Dis. 143, 522–527.
- [5] Lai, C.C. and Finlayson-Pitts, B.J. (1991) Lipids 26, 306-314.
- [6] Mohensin, V. and Gee, J.B.L. (1987) Am. Rev. Resp. Dis. 136, 646–650.
- [7] Norman, V. and Keith, C.H. (1965) Nature 205, 915-916.
- [8] Pryor, W.A., Tamura, M. and Church, D.F. (1984) J. Am. Chem. Soc. 106, 5073–5079.
- [9] Moncada S., Palmer, R.M.J. and Higgs, E.A. (1991) Pharm. Rev. 43, 109-142.
- [10] Radi, R., Beckman, J.S., Bush, K.M. and Freeman, B.A. (1991) Arch. Biochem. Biophys. 288, 481–487.
- [11] Arroyo, P.L., Hatch-Pigott, V., Mower, H.F. and Cooney, R.V. (1992) Mut. Res. 281, 193-202.
- [12] Nguyen, T., Brunson, D., Crespi, C.L., Penman, B.W., Wishnock, J.S. and Tannenbaum, S.R. (1992) Proc. Natl. Acad. Sci. USA 89, 3030–3034.
- [13] Elstner, E.F. and Osswald, W. (1991) Free Radical Res. Commun. 12, 759-807.
- [14] Thomas, H.V., Mueller, P.K. and Lyman, R.L. (1967) Science 159, 532–534.
- [15] Sagai, M. and Ichinose, T. (1991) Toxicology 66, 121-132.
- [16] Cavanagh, D.G. and Morris, J.B. (1987) J. Tox. Environ. Health 22, 313–328.
- [17] Halliwell, B. and Gutteridge, J.M.C. (1990) Arch. Biochem. Biophys. 280, 1–8.
- [18] Frei, B. and Ames, B.N. (1992) in: Molecular Biology of Free Radical Scavenging Systems (J. Scandalios, ed.) Cold Spring Harbor Press, New York, pp. 23-45.
- [19] Postlethwait, E.M., Langford, S.D. and Bidani, A. (1991) Toxicol. Appl. Pharmacol. 109, 464–471.
- [20] Csallany, A.J. and Ayaz, K.L. (1978) Toxicol. Lett. 2, 97-107.
- [21] Menzel, D.B. (1979) Environ. Health. Perspect. 29, 105-113.
- [22] Cross, C.E., Motchnik, P.A., Bruener, B.A., Jones, D.A., Kaur, H., Ames, B.N. and Halliwell, B. (1992) FEBS Lett. 298, 269-272.
- [23] Frei, B., Stocker, R. and Ames, B.N. (1989) Proc. Natl. Acad. Sci. USA 86, 6377-6381.
- [24] Levine, R.L., Garland, D., Oliver, C.N., Amici, A., Climent, I., Lenz, A.G., Ahn, B.W., Shaltiel, S. and Stadtman, E.R. (1990) Methods Enzymol. 186, 464-478.
- [25] Yamamoto, Y., Brodsky, M.H., Baker, J.C. and Ames, B.N. (1987) Anal. Biochem. 160, 7-13.
- [26] Freeman, G., Stephens, R.J., Crane, S.L. and Furiosi, N.J. (1968) Arch. Environ. Health 17, 181-182.
- [27] U.S. Government Printing Office (1988) Code of Federal Regulations 40, 685–695.

ŝ

- [28] Driskell, W.J., Neese, J.W., Bryant, C.C. and Bushor, M.M. (1982) J. Chromatogr. 231, 439-444.
- [29] Hu, M.L. and Tappel, A.L. (1992) Photochem. Photobiol. (in press).
- [30] Stocker, R., Bowry, V.W. and Frei, B. (1991) Proc. Natl. Acad. Sci. USA 88, 1646–1650.
- [31] Kagan, V.E., Serbinova, E.A. and Packer, L. (1990) Biochem. Biophys, Res. Commun. 169, 851-857.
- [32] Davis, W.B. and Pacht, E. (1991) in: The Lung: Scientific Foundations, (R.G. Crystal and J.B. West, eds.) pp. 1821–1827, Raven Press, New York.
- [33] Hatch Jr., G.E. (1991) in: Comprehensive Treatise on Pulmonary Toxicology, vol. 1, (R. Parent, ed.) pp. 617–632, CRC Press, Boca Raton.

- [34] Maples, K.R. and Mason, R.P. (1988) J. Biol. Chem. 263, 1709– 1712.
- [35] Aruoma, O.I. and Halliwell, B. (1989) FEBS Lett. 244, 76-80.
- [36] Sagai, M., Ichinose, T. and Kubota, K. (1984) Toxicol. Appl. Pharmacol. 73, 444-456.
- [37] Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C. and Witztum, T.L. (1989) N. Engl. J. Med. 320, 915-924.
- [38] Peden, D.B., Hohman, R., Brown, M.E., Mason, R.T., Bethebile, C., Fales, H.M. and Kaliner, M.A. (1991) Proc. Natl. Acad. Sci. USA 87, 7638-7642.
- [39] Cross, C.E., Reznick, A.Z., Packer, L., Davis, P.A., Suzuki, Y.J. and Halliwell, B. (1992) Free Radical Res. Commun. 15, 347–352.
- [40] Gelzleichter, T.R., Witschi, H. and Last, J.A. (1992) Toxicol. Appl. Pharmacol. 112, 73-80.